Syngene International: Could India’s WuXi moment finally be here?

▤ Summary

Syngene International faces a tough FY26, but the article argues that the company’s long-term capability build is starting to align with a major market shift. The Pentagon’s designation of WuXi AppTec strengthens the case for pharmaceutical companies to diversify away from Chinese CRDMOs. Syngene already has discovery, development, and manufacturing capabilities that match the needs of complex biologics, ADCs, and next-generation therapies. The extension of its Bristol Myers Squibb collaboration through 2035 adds validation and long-term visibility. The main opportunity lies in new outsourcing demand from global pharma companies reassessing their supply chains and strategic partners.

▦ Linked Companies